A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma

18F-fluorodeoxyglucose PET-CT may guide treatment decisions in patients with oesophageal adenocarcinoma (OAC). This study evaluated the added value of maximum standardised uptake value (SUVmax) to a novel DNA-damage immune response (DDIR) assay to improve pathological response prediction. The diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Foley, Kieran G., Lavery, Anita, Napier, Eoin, Campbell, David, Eatock, Martin M., Kennedy, Richard D., Bradley, Kevin M., Turkington, Richard C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219719/
https://www.ncbi.nlm.nih.gov/pubmed/34158588
http://dx.doi.org/10.1038/s41598-021-92545-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219719/
https://www.ncbi.nlm.nih.gov/pubmed/34158588
http://dx.doi.org/10.1038/s41598-021-92545-w

Ejemplares similares